Monica Dugăeşescu

Dr. Monica Dugăeşescu

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 November 2025 in Hemato
Verified
Journal Article
Open access
PDF file
MDMonica Dugăeşescu
Monica Dugăeşescu
IAIulia Andrei-Bitere
Iulia Andrei-Bitere
MBMarina Raluca Baciu
Marina Raluca Baciu
EDEva Dănescu
Eva Dănescu
ALAlexandru Liţescu
Alexandru Liţescu
EPElena Poenaru
Elena Poenaru
Background/Objectives: Complete blood count (CBC)-derived markers such as the neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and lymphocyte-to-monocyte ratio (LMR) have gained increasing attention as accessible indicators of systemic inflammation. These parameters, calculated from routine blood tests, are widely available in clinical settings and are potentially relevant for a variety of chronic diseases. This review aims to explore current evidence and highlight potential future directions regarding the use of hematologic inflammatory biomarkers in chronic disease. Methods: We performed an extensive literature search on PubMed to identify full-text original studies published in the past five years, focused on investigating the clinical applications of hematologic inflammatory markers in chronic conditions. Results: CBC-derived inflammatory markers have been studied in a wide range of chronic diseases, including autoimmune diseases, metabolic disorders, chronic kidney disease, chronic infections, psychiatric diseases, and other conditions. These markers have been evaluated for multiple clinical purposes, such as aiding diagnosis, monitoring disease status, assessing disease activity, disease subtype characterization, predicting prognosis, and evaluating associations with disease outcomes. Conclusions: As chronic diseases affect millions of individuals globally, placing a burden for the healthcare system, patients, and their families, simple and cost-efficient tools like CBC-derived inflammatory markers have the potential to improve clinical case management.

Verified
Journal Article
Open access
PDF file
Mihnea-Alexandru GamanMihnea-Alexandru Gaman
Mihnea-Alexandru Gaman
MDMonica Dugăeşescu
Monica Dugăeşescu
Dragos Claudiu PopescuDragos Claudiu Popescu
Dragos Claudiu Popescu
Background. Acute promyelocytic leukemia (APL) is a subtype of acute myeloid leukemia defined by the presence of a genetic abnormality, namely the PML::RARA gene fusion, as the result of a reciprocal balanced translocation between chromosome 17 and chromosome 15. APL is a veritable emergency in hematology due to the risk of early death and coagulopathy if left untreated; thus, a rapid diagnosis is needed in this hematological malignancy. Needless to say, cytogenetic and molecular biology techniques, i.e., fluorescent in situ hybridization (FISH) and polymerase chain reaction (PCR), are essential in the diagnosis and management of patients diagnosed with APL. In recent years, the use of artificial intelligence (AI) and its brances, machine learning (ML), and deep learning (DL) in the field of medicine, including hematology, has brought to light new avenues for research in the fields of blood cancers. However, to our knowledge, there is no comprehensive evaluation of the potential applications of AI, ML, and DL in APL. Thus, the aim of the current publication was to evaluate the prospective uses of these novel technologies in APL. Methods. We conducted a comprehensive literature search in PubMed/MEDLINE, SCOPUS, and Web of Science and identified 20 manuscripts eligible for the qualitative analysis. Results. The included publications highlight the potential applications of ML, DL, and other AI branches in the diagnosis, evaluation, and management of APL. The examined AI models were based on the use of routine biological parameters, cytomorphology, flow-cytometry and/or OMICS, and demonstrated excellent performance metrics: sensitivity, specificity, accuracy, AUROC, and others. Conclusions. AI can emerge as a relevant tool in the evaluation of APL cases and potentially contribute to more rapid screening and identification of this hematological emergency.

11 November 2025 in Data
Verified
Journal Article
Open access
PDF file
EPElena Poenaru
Elena Poenaru
MDMonica Dugăeşescu
Monica Dugăeşescu
CPCalin Poenaru
Calin Poenaru
IAIulia Andrei-Bitere
Iulia Andrei-Bitere
Livia-Cristiana Băicoianu-NițescuLivia-Cristiana Băicoianu-Nițescu
Livia-Cristiana Băicoianu-Nițescu
SSSmaranda Stoleru
Smaranda Stoleru
Background: Research in personalized medicine, with applications in oncology, dermatology, cardiology, urology, and general healthcare, requires facile and safe access to accurate data. Due to its particularly sensitive character, obtaining health-related data, storing it in repositories, and federating it are challenging, especially in the context of open science and FAIR data. Methods: An online survey was conducted among medical researchers to gain insights into their knowledge and experience regarding the following topics: health data repositories and data federation, as well as their opinions regarding data sharing and their willingness to participate in sharing data. Results: The survey was completed by 189 respondents, the majority of whom were attending physicians and PhD candidates. Most of them acknowledged the complex, beneficial implications of data federation in the medical field but had concerns about data protection, with 75% declaring that they would agree to share data. A general lack of awareness (80%) about the importance of interoperability for federated data repositories was observed. Conclusions: Implementing federated data repositories in the health field requires thorough understanding, knowledge, and collaboration, enabling translational medicine to reach its full potential. Understanding the needs of all involved parties can shape the success of medical data federation initiatives, with this study serving as a foundation for further research.

22 September 2026 in Antibiotics
Verified
Journal Article
Open access
PDF file
ABAnda Baicus
Anda Baicus
VSValentina Daniela Sisu
Valentina Daniela Sisu
ATAndreia Tatar
Andreia Tatar
LBLore-Dana Barcer
Lore-Dana Barcer
EBElena-Andreea Birlescu
Elena-Andreea Birlescu
CCCatalin Cirstoiu
Catalin Cirstoiu
Background/Objectives: Carbapenem-resistant Gram-negative bacteria—especially NDM- and OXA-48-producing Klebsiella pneumoniae and carbapenem-resistant Acinetobacter baumannii (CRAB)—have limited treatment options, and in vitro data from Eastern Europe on the reserve agents eravacycline, aztreonam–avibactam, and cefiderocol are scarce. We evaluated their in vitro activity against consecutive multidrug-resistant (MDR) Gram-negative isolates from a Romanian tertiary hospital, stratified by species and carbapenemase profile. Methods: Seventy-seven consecutive, non-duplicate MDR Gram-negative isolates were collected over a 12-week period (January–March 2026) at a single tertiary center and tested by gradient diffusion (Liofilchem MIC Test Strip). MTS was used as an exploratory screening method; reference broth microdilution (BMD) remains the standard for categorical susceptibility confirmation. MICs were interpreted using FDA and EUCAST v16.0 breakpoints. Carbapenemases were detected by immunochromatography (18 isolates), and carbapenemase-encoding genes were detected by Xpert Carba-R PCR (40 isolates of K. pneumoniae). Susceptibility is reported with Wilson 95% confidence intervals. Results: K. pneumoniae (n = 51) predominated; NDM+OXA-48 was the most common profile (43.1%), and NDM was present in 64.7%. Eravacycline inhibited 90.2% of K. pneumoniae, and aztreonam–avibactam inhibited 92.2%, both covering all NDM-only isolates (9/9). Cefiderocol inhibited 84.3% of K. pneumoniae overall, but only 6/9 (66.7%) of NDM-only producers versus 20/22 (90.9%) of NDM+OXA-48 co-producers, whereas eravacycline and aztreonam–avibactam remained active against all nine NDM-only isolates. Cefiderocol was the only agent active against P. aeruginosa (91.7%); aztreonam–avibactam showed uniformly high MICs against non-fermenters, and all 10 CRAB isolates had low eravacycline MICs (MIC50 0.064 µg/mL). Conclusions: The three agents were complementary: aztreonam–avibactam and eravacycline covered NDM-producing K. pneumoniae, whereas cefiderocol was less active in vitro; cefiderocol alone covered P. aeruginosa. Because MICs were generated by gradient diffusion, these exploratory benchmarks require confirmation by reference broth microdilution; gradient strips agree well with BMD for aztreonam–avibactam but show weaker, agent-dependent agreement for eravacycline and cefiderocol, so they are not yet a validated substitute across all three agents.

10 November 2026 in Journal of Fungi
Verified
Journal Article
Open access
PDF file
VSValentina Daniela Sisu
Valentina Daniela Sisu
ATAndreia Tatar
Andreia Tatar
MDMonica Dugăeşescu
Monica Dugăeşescu
LBLore-Dana Barcer
Lore-Dana Barcer
ABAnda Baicus
Anda Baicus
This study aimed to evaluate the species distribution and antifungal susceptibility profiles in Candida spp. isolates over a 17-month period in a tertiary care hospital from Bucharest, Romania. A total of 108 isolates retrieved from inpatients and outpatients were identified by MALDI-TOF and tested for susceptibility against a YO10 nine-agent panel provided by SensiTitreTM. Among the selection criteria for isolates were the sample’s origin and laboratory procedures used for antifungal testing. The MICs were interpreted according to the current CLSI breakpoints (M27M44S) and current ECVs (M57S). From a total of 92 Candida isolates with defined susceptibility breakpoints, 77 isolates (83.69%) were susceptible to fluconazole, and additionally, 11 N. glabratus (11/12, one isolate resistant) were evaluated as susceptible-dose dependent (SDD). C. albicans was the most frequently isolated species, accounting for 56.48% of all strains (61/108 isolates). Susceptibility to fluconazole in this subgroup was 86.88% (53/61 isolates). Non-albicans species were represented by a total of 47 isolates (43 with established breakpoints). The fluconazole susceptibility rate was 83.87% (26/31 isolates), notably lower than C. albicans isolates, and it was calculated by excluding N. glabratus isolates. The finding of fluconazole-resistant C. parapsilosis sensu stricto in blood cultures (3 of 6 isolates) is clinically relevant. Although this is a small exploratory comparison, the result is in line with the Southern-European signal (ECMM Candida III). Echinocandins resistance rate (Anidulafungin, Micafungin, Caspofungin) was low (2.85%, 3/105 strains with defined susceptibility cut-offs) but not alternatively documented, with MICs ranging from 1 to 4 μg/mL in two C. albicans and one C. tropicalis isolate. This study underscores the importance of tracking local epidemiological data and antifungal susceptibility patterns given the diversity of patient groups in large medical units.